Signal transducer and activator of transcription 3 (Stat3) is the major mediator of interleukin-6 (IL-6) family cytokines. In addition, Stat3 is known to be involved in the pathophysiology of many malignancies. Here, we show that the cis-trans peptidyl-prolyl isomerase cyclophilin (Cyp) B specifically interacts with Stat3, whereas the highly related CypA does not. CypB knockdown inhibited the IL-6-induced transactivation potential but not the tyrosine phosphorylation of Stat3. Binding of CypB to Stat3 target promoters and alteration of the intranuclear localization of Stat3 on CypB depletion suggested a nuclear function of Stat3/CypB interaction. By contrast, CypA knockdown inhibited Stat3 IL-6-induced tyrosine phosphorylation and nuclear translocation. The Cyp inhibitor cyclosporine A (CsA) caused similar effects. However, Stat1 activation in response to IL-6 or interferon-c was not affected by Cyp silencing or CsA treatment. As a result, Cyp knockdown shifted IL-6 signaling to a Stat1-dominated pathway. Furthermore, Cyp depletion or treatment with CsA induced apoptosis in IL-6-dependent multiple myeloma cells, whereas an IL-6-independent line was not affected. Thus, Cyps support the anti-apoptotic action of Stat3. Taken together, CypA and CypB both play pivotal roles, yet at different signaling levels, for Stat3 activation and function. These data also suggest a novel mechanism of CsA action.
Introduction
Signal transducer and activator of transcription-3 (Stat3) has a key regulatory role in various cytokinecontrolled cellular processes such as differentiation, proliferation and cell survival. Stat3 has been first described by us as a central component of interleukin-6 (IL-6) signaling, which mediates the IL-6-induced production of acute phase proteins in hepatocytes (Wegenka et al., 1993; Yuan et al., 1994) . Activation of Stat3 occurs through phosphorylation of tyrosine 705, mediated by receptor-associated janus (JAK) protein tyrosine kinases . The factor translocates to the nucleus where it binds to regulatory elements of target genes, controlling their transcription . In addition to IL-6, other cytokines, growth factors and hormones have been shown to activate Stat3, which is now known to be involved in a variety of physiological processes, including functions during development, in the immune system, and homeostasis in many organs and tissues. Dysregulation of Stat3 signaling is involved in etiology and/or progression of various diseases, for example, autoimmune and chronic inflammatory diseases, as well as cancer. In fact, being activated in many cancers, Stat3 is now widely regarded as an oncoprotein (Hodge et al., 2005) . Stat3 is essential for transformation induced by various oncogenes, and a constitutively active Stat3 mutant causes cellular transformation (Bromberg et al., 1999) . In many cancer cells, Stat3 signaling has been recognized as a pivotal pathway supporting survival and growth (Schwarze and Hawley, 1995; Catlett-Falcone et al., 1999; Rawat et al., 2000; Puthier et al., 2001) .
The Stat3 signaling is modulated, both positively and negatively, by its interaction with numerous other proteins, and crosstalk occurs with various other signaling cascades, including the NF-kB, AP-1 or PI-3K pathways. Here, we show that Stat3 activation and function are supported by the cyclophilins (Cyps) A and B, both targets of the immunosuppressive drug cyclosporine A (CsA). Cyps are members of the immunophilin family of proteins that show peptidyl-prolyl cis-trans isomerase (PPIase) activity. They are highly conserved in the phylogenetic tree, from archaebacteria to vertebrates, suggesting a crucial role in the function of living cells (Wang and Heitman, 2005) .
Cyclophilin A is best known for its role in inhibiting calcineurin in a complex with CsA (Wang and Heitman, 2005) . Furthermore, CypA is involved in multiple signaling events, for example, it regulates IL-2 tyrosine kinase activity (Brazin et al., 2002) , is required for retinoic acid-induced neuronal differentiation (Song et al., 2004) and modulates prolactin receptor signaling (Syed et al., 2003) . CypA also affects gene expression by physically interacting with transcription factors and histone-modifying enzymes (Arevalo-Rodriguez et al., 2000; Cui et al., 2002) . CypB was also described to be involved in signal transduction pathways and transcriptional control (Rycyzyn et al., 2000; Rycyzyn and Clevenger, 2002; Obata et al., 2005) . Furthermore, both CypA and CypB are secreted from cells in response to inflammatory stimuli (Sherry et al., 1992; De Ceuninck et al., 2003) . Secreted CypA has multiple functions in chemotaxis and cell signaling through its cellular receptor, CD147 (Yang et al., 2008) . Both CypA and CypB are found in high concentrations in the synovial fluid of arthritic joints, suggesting their role in chronic inflammatory diseases (Billich et al., 1997; De Ceuninck et al., 2003) .
Here, we show that both CypA and CypB support Stat3 signaling, yet at different levels of the pathway. While CypB/Stat3 interaction seems functionally relevant mainly in the nucleus, CypA is required to allow maximal Stat3 tyrosine phosphorylation and nuclear translocation. Both Cyps proved to be required for the survival of Stat3-dependent multiple myeloma cells.
Results

Stat3 interacts specifically with CypB
To identify proteins that interact with Stat3, we analysed proteins co-immunoprecipitated with Stat3 from lysates of HepG2 human hepatocellular carcinoma cells using mass spectrometry as described in Materials and methods. To also identify protein interactions that are not sufficiently stable to withstand lysis and precipitation procedures, we chose to crosslink the living cells beforehand using a chemical crosslinker. This approach identified, among others, CypB as a novel Stat3 interactor. As shown in Figure 1a , the interaction of Stat3 and CypB could be verified in HepG2 lysates by immunoprecipitation and subsequent immunoblotting in both directions. The interaction was detected in untreated HepG2 cells and slightly increased on IL-6 stimulation. This suggests that Stat3 activation, though not a prerequisite, may support the association of the two proteins. In contrast to CypB, the highly related CypA was not found to interact with Stat3 ( Figure 1b) . Treatment with the immunosuppressant CsA, known to bind and inhibit the enzymatic activity of Cyps, reduced but did not abolish Stat3/CypB interaction ( Figure 1c) .
The CypA and CypB are highly homologous within their catalytic core domains. The latter, however, possesses additional amino-and carboxy-terminal sequences comprising a signal peptide and an endoplasmic reticulum retention sequence, respectively. Consequently, intracellular CypB is mainly found associated with the endoplasmic reticulum compartment (Wang and Heitman, 2005) . By contrast, Stat3 is preferentially cytoplasmic in untreated HepG2 cells and translocates to the nucleus on activation in response to IL-6.
To analyse in which cellular compartment the interaction of Stat3 and CypB may take place, CypB intracellular localization in untreated or IL-6-stimulated HepG2 cells was studied by indirect immunofluorescence. In untreated cells, CypB was found preferentially in a perinuclear distribution and in lower amounts in the nucleus and cytoplasm (Figure 2a) . Interestingly, after treatment with IL-6, CypB redistributed to a cytoplasmic and nuclear localization in approximately 10% of the cell population. To characterize this process further, a carboxy-terminal fusion of CypB with yellow fluorescent protein (YFP) was constructed and analysed in HepG2 cells. Co-transfection of the endoplasmic reticulum marker DsRed-ER showed that the bulk of CypB-YFP colocalized with that compartment (Figure 2b 
Functional importance of Cyps for Stat3 activation and function
To analyse a physiological function of the CypB/Stat3 interaction in living cells, we investigated the influence of CypB on the expression of the Stat3-specific gene regulation using reporter gene analysis. Overexpression of CypB in HepG2 cells yielded a small but significant increase in the Stat3-dependent promoter activity of the a 1 -antichymotrypsin (ACT) gene (Figure 3a) .
Unexpectedly, overexpression of CypA caused a comparable increase in ACT promoter activity. By contrast, the IL-6-unresponsive promoter of the herpes virus thymidine kinase (tk) gene was not supported by Cyp overexpression, suggesting that the observed effect is specific for the Stat3-regulated promoter. In contrast to wild-type CypB, a catalytically compromised mutant (CypB-DPPI) did not show any effect on ACT promoter activity (Figure 3b ), suggesting that PPIase activity is required for CypB to act on Stat3 signaling.
As reported earlier, extracellular CypB supports prolactin/prolactin receptor/Stat5 signaling, is internalized together with prolactin, and was shown to support the transactivating potential of Stat5 in the nucleus (Rycyzyn et al., 2000; Rycyzyn and Clevenger, 2002) . As secretion of CypB is enhanced under inflammatory circumstances, we figured that its IL-6-driven redistribution as observed above might reflect a secretion/ reuptake pathway, and that the effects of CypB on Stat3 function might be due to internalized CypB. In fact, recombinant CypB, when added to the medium of HepG2 cells, increased the IL-6-induced activity of the ACT promoter to a comparable extent, as did intracellular overexpression (data not shown).
The moderate CypB-induced increase in ACT promoter activity likely reflects the fact that most cells express rather high protein levels of CypB. Therefore, we next used RNA interference to investigate the influence of a Cyp knockdown on Stat3. Expression of small hairpin RNAs targeting either CypA or CypB mRNAs yielded a reduction but not complete depletion of Cyp protein levels (see Supplementary Figure 1 ). This is most likely due to the rather slow turnover of Cyp proteins. When tested by luciferase reporter assays in HepG2 cells, knockdown of either Cyp significantly inhibited Stat3-driven ACT promoter activity ( Figure 3c ). This leads to the conclusion that, in accordance with the overexpression studies above, both CypA and CypB support Stat3 function.
To investigate the level of Stat3 signaling the Cyps act on, we next studied whether their knockdown interferes with IL-6-induced activation of Stat3, that is, phosphorylation of tyrosine residue 705. To this purpose, HepG2 cells were transiently transfected with small hairpin RNA vectors as above, together with an expression vector for a Stat3-YFP fusion protein that we showed earlier to be fully functional . This fusion protein allowed us to selectively monitor Stat3 tyrosine phosphorylation in the transfected cells. As shown in Figure 4a , Stat3 phosphorylation was not affected by a knockdown of CypB but was clearly inhibited by CypA depletion.
The IL-6 activates not only Stat3 but also the highly related Stat1. This raised the question whether the observed inhibitory effect of CypA silencing represents a general block of IL-6 signaling or whether it may be specific for Stat3 activation. As shown in Figure 4b , neither CypB nor CypA knockdown inhibited Stat1 activation. Likewise, Stat1 phosphorylation in response to interferon-g remained unchanged ( Figure 4c ). Taken together, these data suggest that CypA specifically contributes to Stat3 signaling at the level of tyrosine phosphorylation, whereas the supportive effect of CypB acts on a level distal from Stat3 activation.
The ACT promoter is specifically transactivated by Stat3 but not by Stat1 (FH, unpublished results). Given our observation that CypA depletion inhibited Stat3, but not Stat1 activation, the question arises how genes that are targets for either factor respond to a CypA knockdown. Using reporter gene assays with the promoter of the intercellular adhesion molecule-1 (ICAM-1) gene that is strongly induced by both IL-6 and interferon-g, we observed an increased rather than decreased luciferase activity on Cyp silencing ( Figure 4d ). It is noted that this was true for both Cyps, suggesting that the supportive role of CypB is Stat3-specific as well.
The Stat3 tyrosine phosphorylation is followed by translocation of the factor to the nucleus. We therefore next studied whether the interaction with CypB might influence this translocation process. Stat3-YFP was expressed by transient transfection in HepG2 cells and its subcellular distribution visualized by fluorescence Figure 2, part A) . However, when cells were studied 72 h after transfection (a time point where CypB knockdown was more effective), the situation changed: Although the cytoplasmic distribution of nonactivated Stat3 remained unaffected, Stat3 accumulated in the nucleus of a majority of cells in a dotlike pattern. This result shows that CypB silencing does not impede nuclear accumulation of Stat3 but affects its intranuclear distribution ( Figure 5 ).
The subcellular localization of a Stat1-YFP fusion protein was studied in human embryonic kidney 293 cells stimulated through either the interferon-g or the IL-6 pathway. Owing to the low levels of IL-6 receptor a subunits in these cells, stimulation was performed with hyper-IL-6, a fusion protein of IL-6 and the soluble IL-6 receptor a that acts directly on the signal transducing gp130 subunit of the IL-6 receptor (Peters et al., 1998) . Neither CypA nor CypB silencing blocked Stat1 nuclear translocation. This was obvious both 48 h (Supplementary Figure 2 , part B) and 72 h post-transfection (not shown).
As evident from the above data, CypB/Stat3 interaction affects nuclear functions and localization of the transcription factor. Hence, we reasoned that CypB might interact with the carboxy-terminal transactivation domain of Stat3 and/or might associate with Stat3 target promoter regions. Co-immunoprecipitation experiments using a truncated Stat3 mutant lacking the transactivation domain (Stat3-D715) showed that it is not required for the Stat3/CypB interaction ( Figure 6a ). However, chromatin immunoprecipitation (ChIP) studies in HepG2 cells indicated an association of CypB with the Stat3-binding region of the ACT gene (Figure 6b ). ChIP analysis of the endogenous ACT gene generally produced low signals in HepG2 cells. Therefore, we extended the studies to additional Stat3 target genes, that is, the junB and haptoglobin genes (Figure 6c ). The data show strong binding of CypB even in the absence of IL-6 stimulation. On IL-6 Figure 3 The transactivation potential of Stat3 is supported by cyclophilins (Cyps). (a, b) Luciferase reporter assays in HepG2 cells: cells were transiently transfected with expression vectors qfor CypA, CypB, CypB-DPPI or with a control vector (ctr). a 1 -antichymotrypsin (ACT) promoter luciferase construct (pACT-Luc) and b-galactosidase (b-gal) expression vector under the control of the early SV40 T antigen promoter were cotransfected. At 48 h after transfection, cells were treated without or with interleukin-6 (IL-6) (10 ng/ml) for 4 h and harvested thereafter. Luciferase activities as determined in the cell lysates were normalized to b-gal activities to account for transfection efficiency. (c) HepG2 cells were transfected with pSUPERshCypA, pSUPER-shCypB or an empty pSUPER (ctr). After 72 h, the cells were treated without or with IL-6 for 4 h and the luciferase and b-gal activities were measured. All values represent the means of three independent experiments, ± standard deviation. tk, tyrosin kinase. (Figure 6c) . In contrast to CypB, we could not detect any considerable association of CypA with the promoters tested. (Figure 7b and c). To determine whether CsA-induced apoptosis occurred through the extrinsic or intrinsic pathway, we measured caspase 8 and 9 cleavage in INA-6 cells (see Supplementary Figure 3a and b). Both caspases were found to be inducibly cleaved, indicating that both the receptor-dependent and the mitochondrial apoptosis pathways are activated by CsA. Studies with inhibitors specific for caspase 8 or 9 supported this view (Supplementary Figure 3c) . Furthermore, we observed reduced levels of Mcl-1 on CsA treatment in INA-6 cells ( Supplementary Figure 3d) , the only Bcl-2 family member found previously to be upregulated in these cells in response to IL-6 (Brocke-Heidrich et al., 2004) .
To further substantiate a role for Cyps in myeloma cell survival, we next silenced CypA and CypB by transfecting the IL-6-dependent myeloma lines INA-6 and XG-1 with small hairpin RNA vectors as described above for HepG2 cells. As a control, we included the IL-6-independent myeloma line MM1.S in the study. Cells were co-transfected with an expression vector encoding enhanced green fluorescent protein to allow gating for transfected cells during flow cytometric analyses. As evident from Figure 8 , knockdown of either CypA or CypB yielded similar rates of apoptosis induction as did a Stat3 knockdown in both INA-6 and XG-1 cells. However, neither Stat3 nor Cyp knockdown induced apoptosis in MM1.S cells. Therefore, there is a close correlation between the anti-apoptotic actions of Cyps and Stat3 in myeloma cells.
As discussed above, CypB might at least partially act on Stat3 signaling as the secreted form after its reuptake by the cell. In fact, when CypB-depleted XG-1 cells were reconstituted by the addition of recombinant CypB to the medium, apoptosis induction was significantly reduced (Figure 8d ). The catalytically inactive mutant CypB-PPI was completely ineffective in that respect, proving the requirement of PPIase activity for this CypB action. Likewise, when INA-6 cells were cultivated under reduced levels of IL-6 (0.1 ng/ml), resulting in a moderate induction of apoptosis, treatment with recombinant CypB protein caused a significant decrease of the apoptotic poly-(ADP-ribose) polymerase Immunoprecipitation and immunoblotting were performed with antibodies to CypB and Stat3, respectively. (b, c) HepG2 cells, untreated or treated with interleukin-6 (IL-6) for 30 min, were subjected to a chromatin immunoprecipitation (ChIP) assay using CypB, CypA or Stat3 antibodies, or to control immunoglobulins. The isolated DNA was analysed by PCR using primers specific for the Stat3-binding regions of the a 1 -antichymotrypsin (ACT) (b) or junB and haptoglobin promoters (c). As a control, the upstream region of the b-actin gene was used. Total chromatin (input) was used as a template for haptoglobin PCR to show equal amounts of the starting material. Stat3, signal transducer and activator of transcription 3.
Interaction of Stat3 with cyclophilin B K Bauer et al fragments, again indicative of a protective effect of CypB treatment (Supplementary Figure 3e) .
Taken together, we conclude that CypA and CypB support myeloma cell survival, most likely through their action on Stat3 signaling.
Discussion
There is growing evidence for a role of PPIases in transcriptional control. Various PPIases were found to interact with transcription factors and affect their activity. This includes the inhibitory action of Cyp-40 and FKBP52 on cMyb and IRF-4, respectively, and the supportive interaction of CypB with IRF-3 (Leverson and Ness, 1998; Mamane et al., 2000; Obata et al., 2005) . Furthermore, pin1 interacts with NF-kB p65, the tumor suppressor p53, as well as Stat3 supporting their transactivating potential (Zacchi et al., 2002; Ryo et al., 2003; Lufei et al., 2007) . CypB was shown to interact with another member of the STAT family, Stat5 (Rycyzyn and Clevenger, 2002) . In breast cancer cells, this interaction enhances the transcriptional activity of Stat5, most likely by supporting Stat5 DNA binding and release of the inhibitor PIAS3. Hence, the interaction of CypB and Stat3 as reported here is not entirely unexpected. Binding of CypB to Stat3 was observed only when cells were crosslinked, indicating either lowaffinity binding or a high on/off rate. In fact, we were recently able to verify Stat3/CypB interaction in vitro by surface plasmon resonance studies, and these data indicate a limited but significant affinity between the two proteins and substantiate the requirement of the CypB PPIase activity for their interaction (manuscript in preparation).
In contrast to pin1 that binds to the transactivation domain of Stat3, CypB association did not depend on that domain. This is in line with the observation that CypB interacts with an amino-terminal part of Stat5 (Rycyzyn and Clevenger, 2002) . As observed for Stat5, CypB supported the transactivating potential of Stat3 toward a Stat3-specific target promoter. This was shown by both ectopic overexpression and silencing of CypB. Although the underlying mechanism is not yet clear, our data provide evidence that Stat3/CypB interaction is a nuclear phenomenon. This view is further supported by the presence of CypB at Stat3 target promoters. As this association was most significant in the absence of IL-6 stimulation, it needs to be clarified how CypB is directed specifically to such promoter regions. CypB silencing did not inhibit Stat3 tyrosine phosphorylation and nuclear translocation but caused Stat3 to localize at punctuate structures within the nucleus reminiscent of promyelocytic leukemia bodies. As promyelocytic leukemia bodies are associated with PIAS proteins and SUMOylation activity, this observation suggests that-as in the case of Stat5-CypB might release a PIAS factor from Stat3.
The CypB is expressed in many tissue types and resides mostly within the endoplasmic reticulum. Secretion of CypB can yield appreciable protein levels in blood and milk, and is significantly increased by inflammatory stimuli (Mariller et al., 1996; Bukrinsky, 2002) . Subsequently, it is immobilized on the cell surface through interaction with proteoglycans. The fact that CypB is an intrinsic component of cartilage, is found in high concentrations in the rheumatoid arthritis synovial fluid, and that it can be released by matrix metallopro- Figure 7 Cyclosporine A (CsA) inhibits myeloma cell survival and growth. (a) INA-6 (left) myeloma cells were cultivated in the presence or absence of interleukin-6 (IL-6) (1 ng/ml) for 12 h, without or with CsA (80 mM) as indicated. Apoptosis was determined by flow cytometric annexin V assay. Values indicate viable annexin V and propidium iodide-negative cells. XG-1 cells (right) were cultivated in the presence or absence of IL-6 (2 ng/ml) for 72 h, without or with CsA (80 mM) as indicated. Cell cycle was measured using flow cytometric propidium iodide staining as described in Materials and methods. All data represent means±s.d. from three independent experiments. (b) INA-6 cells cultivated in the presence of IL-6 (1 ng/ml) were incubated with CsA (10 mM) or solvent control (ctr) for the time period indicated. Thereafter, cell lysates were subjected to immunoblotting using antibodies to phospho-Stat3, Stat3 and b-actin. (c) INA-6 cells cultivated with IL-6 (1 ng/ml) were incubated with interferon g (1000 U/ml) for the time period indicated, in the presence of CsA (10 mM) or solvent control (ctr). Cell lysates were then analysed by immunoblotting using antibodies to phospho-Stat1, Stat1 and b-actin. Stat3, signal transducer and activator of transcription 3.
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K Bauer et al teinases from the surface of chondrocytes, suggests that it has a role in the pathogenesis of arthritic diseases (De Ceuninck et al., 2003) and possibly other inflammatory and autoimmune diseases. Here, recombinant CypB added to the culture medium showed protective effects toward myeloma cells and was as potent a supporter of transcriptional Stat3 function as was intracellular overexpression. Therefore, it seems possible that nuclear CypB, which interacts with Stat3, principally derives from such a secretion/reuptake pathway and that the redistribution of CypB, which we observe in response to IL-6, reflects such a pathway. This is supported by the finding that CypB supports Stat5-mediated signal transduction and enters the cell in a complex with prolactin (Rycyzyn et al., 2000; Rycyzyn and Clevenger, 2002) . Similar to the IL-6 receptor, the prolactin receptor belongs to the type-I cytokine receptor family. Furthermore, CypB is internalized by T lymphocytes, and the internalization of CypB in complex with CsA induced tolerance of these cells against organ transplants . In fact, preliminary data suggest that the uptake of CypB is accelerated by IL-6 stimulation of HepG2 cells (KB, FH, unpublished results) . The physiological relevance of our observations was further studied in myeloma cell lines, which require activated Stat3 for proliferation and survival (BrockeHeidrich et al., 2004) . CypB knockdown induced apoptosis in these cells to a comparable extent as did Stat3 silencing, suggesting a critical role for the CypB/ Stat3 interaction in this process. It will be interesting to see whether this represents a global mechanism, that is, whether other Stat3-dependent tumor cell lines require CypB for their growth and survival as well.
The involvement of Cyps in myeloma growth and survival as reported here is in line with a growing number of observations on the oncological relevance of CypA and CypB. CypA was found to be overexpressed in many cancer cells, including the pancreas (Shen et al., 2004) and non-small cell lung carcinomas, (Howard et al., 2004) and to render cancer cells resistant to hypoxia-induced cell death (Choi et al., 2007) . CypA knockdown by siRNAs reduced non-small cell lung tumor growth in vivo (Howard et al., 2005) . Likewise, 
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CypB expression is associated with malignant progression of breast cancer (Fang et al., 2009) .
Our data show that CypA and CypB act on the Stat3 pathway at different levels. CypA depletion inhibited Stat3 tyrosine phosphorylation and nuclear translocation. Hence, CypA might interact with the IL-6 receptor complex or indirectly modulate the activity of the receptor-associated JAK tyrosine kinases. In fact, CypA was found to functionally interact with both the prolactin receptor and the JAK2 kinase (Syed et al., 2003) , and this interaction correlates with mammary carcinoma progression (Zheng et al., 2008) . As the IL-6 receptor gp130 subunit is related to the prolactin receptor and also binds JAK2, it seems quite possible that an analogous interaction also takes place at the IL-6 receptor. In addition, IL-6 signaling requires the localization of IL-6 receptors in caveolae (Podar et al., 2003) , and caveolin-1, a protein found in these structures, is also known to interact with CypA (Uittenbogaard et al., 1998) . However, a general inhibition of IL-6 receptor and JAK kinase function by CypA depletion cannot be expected, as we observe that Stat1 phosphorylation is not affected. Stat1 recruitment to gp130 occurs through tyrosine motifs that also recruit Stat3 (Gerhartz et al., 1996) . Therefore, if receptor and/or JAK kinase functions are modulated by CypA, it seems to occur in a target-specific manner. Alternatively, one might also consider that CypA does not act on the receptor level but rather modulates the Stat3 dephosphorylation rate by protein tyrosine phosphatases.
Our findings suggest that the action of CypA is crucial to maintain the dominance of Stat3 over Stat1 signaling in response to IL-6. This might be of particular importance for cells that rely on Stat3 for their survival, as Stat1 is known to preferentially induce pro-apoptotic signals. This conclusion also has interesting implications for the action of CsA. This immunosuppressive drug is successfully used in the treatment of RA (Kitahara and Kawai, 2007) . However, the anti-inflammatory effect of CsA cannot be sufficiently explained by its immunosuppressive function. Therefore, our observation that CsA specifically blocks the Stat3 but not the Stat1 pathway might represent a missing link explaining the action of CsA on inflammatory processes.
Materials and methods
Vector construction
Construction of pSUPER-siStat3, encoding a small-hairpin RNA targeting Stat3, as well as of a control vector (pSUPERscrambled), has been recently described (Brocke-Heidrich et al., 2006) . Sequences encoding a small-hairpin RNA targeting CypA and CypB have been described by Watashi et al. (2005) and were cloned into the BglII and HinDIII sites of pSUPER (Brummelkamp et al., 2002) .
The CypA cDNA was amplified by PCR from pET11c-CypA, a gift from Hans-Georg Kra¨usslich (University Heidelberg, Germany), and inserted into the EcoRI and NotI sites of pcDNA3.1( þ ) (Invitrogen, Karlsruhe, Germany), yielding pcDNA-CypA. Likewise, pcDNA-CypB was amplified by PCR from pcDNA3.1/V5-His-CypB (Rycyzyn et al., 2000) and inserted into the EcoRI and NotI sites of pcDNA3.1( þ ). A vector encoding CypB-YFP was generated by amplifying the CypB cDNA and by inserting it into the BglII/Asp718 site of the vector pEYFP-N1 (Clontech, Saint-Germain-en-Laye, France).
Preparation of recombinant CypB Escherichia coli, strain BL21, were transformed with the expression constructs GST-CypB or GST-CypB-PPI (Rycyzyn and Clevenger, 2002) and cultured in Luria Bertani medium until an optical density of 0.7 was reached. Protein expression was induced by the addition of 1 mM isopropyl b-D-1-thiogalactopyranoside (Sigma Aldrich, Taufkirchen, Germany) to the medium for 4 h. The bacteria were solubilized using a french press as described (Kofron et al., 1991; Rycyzyn and Clevenger, 2002) . Recombinant proteins were purified through coupling to glutathione-Sepharose (Amersham Bioscience, Uppsala, Sweden) and cleavage by 50 units thrombin (Calbiochem, Darmstadt, Germany). The protein was then eluted in phosphate-buffered saline.
Cell culture, transfection and reporter assays Human embryonic kidney 293 cells or HepG2 human hepatoma cells were grown in DMEM F-12 containing 10% FCS and 1% penicillin/streptomycin (all from Life Technologies, Carlsbad, CA, USA). INA-6 and XG-1 myeloma cell lines were cultured in RPMI medium containing 10% FCS, 1% penicillin/streptomycin and IL-6 (1 and 2 ng/ml, respectively). MM1.S myeloma cells were grown in the same medium without the addition of IL-6.
Transfections were carried out using the calcium phosphate co-precipitation technique according to standard protocols. The medium was replaced 6 h after transfection. At 24 h before stimulation, cells were placed in a medium containing 0.5% FCS. For stimulation of human embryonic kidney 293 and HepG2 cells, 10 ng/ml Hyper-IL-6 and 10 ng/ml IL-6, respectively, were used. Both were gifts from Stefan Rose-John (University Kiel, Germany). Interferon-g was from Peprotech (Hamburg, Germany).
For reporter studies, HepG2 cells were grown in six-well tissue culture dishes, transfected with reporter vectors, and luciferase and b-galactosidase assays were conducted as previously described (Brocke-Heidrich et al., 2006) . Myeloma cells were transfected using the Nucleofector technology (Amaxa Inc., Cologne, Germany) according to optimized protocols provided by Amaxa.
Immunoblot analysis Cells were lysed as described (Bellido et al., 1998) . Equal amounts of cellular protein were separated by electrophoresis through an sodium dodecyl sulfate-polyacrylamide gel, proteins transferred to polyvinyldifluoride membrane (Amersham, Buckinghamshire, UK) by semi-dry electroblotting, and immunodetection was performed by standard techniques using chemiluminescence (SuperSignal, West Dura Substrate, Pierce, Rockfort, IL, USA). Anti-phospho-Stat3 (Y705), Stat3, Stat1 and caspase antibodies were obtained from Cell Signaling (Boston, MA, USA) and BD Transduction Laboratories (San Jose, CA, USA), respectively. Polyclonal antibodies against CypB and CypA were from Alexis (Lo¨rrach, Germany). Mcl-1 antibody was from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
